{"filing":{"accession_number":"0001664710-26-000043","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"kros-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000043/kros-20260730.htm"},"events":[{"id":22693,"run_id":20529,"accession_number":"0001664710-26-000043","anchor_item_number":"7.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Keros announced receipt of a $20 million development milestone payment from Takeda under their license agreement for elritercept, triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial. This is a material financial event—a significant cash inflow tied to a clinical milestone—but does not fit the specific categories of debt issuance, dividend distribution, or other named financial events. The company also plans to distribute 25% of net proceeds to stockholders, which has capital allocation implications. This is clearly a financial event but best classified as financial_other rather than operational_other, since the core disclosure is the receipt of contractual milestone payment cash, not the operational achievement itself.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22714,"accession_number":"0001664710-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Keros announced receipt of a $20 million development milestone payment from Takeda under their license agreement for elritercept, triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial. This is a material financial event—a significant cash inflow tied to a clinical milestone—but does not fit the specific categories of debt issuance, dividend distribution, or other named financial events. The company also plans to distribute 25% of net proceeds to stockholders, which has capital allocation implications. This is clearly a financial event but best classified as financial_other rather than operational_other, since the core disclosure is the receipt of contractual milestone payment cash, not the operational achievement itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:32.945276+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22714,"accession_number":"0001664710-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Keros announced receipt of a $20 million development milestone payment from Takeda under their license agreement for elritercept, triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial. This is a material financial event—a significant cash inflow tied to a clinical milestone—but does not fit the specific categories of debt issuance, dividend distribution, or other named financial events. The company also plans to distribute 25% of net proceeds to stockholders, which has capital allocation implications. This is clearly a financial event but best classified as financial_other rather than operational_other, since the core disclosure is the receipt of contractual milestone payment cash, not the operational achievement itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:32.945276+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-07-30"}]}